Study Condition(s): Non-small Cell Lung Cancer

A Study of LY3023414 and Necitumumab in Participants With Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Study Alias: CBBE

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02443337 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years

Time Commitment

Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
  • Participant must have squamous advanced NSCLC (Stage IV)

  • Participant must have progressed on one prior line of platinum-based chemotherapy

  • Participant must be able to swallow the study drug (pills) whole

  • Female participant must not be pregnant or breastfeeding and must agree to have a pregnancy test performed; participants of childbearing potential must agree to use reliable method of birth control during the study and for at least 3 months after stopping study treatment

  • Participant must not have insulin-dependent diabetes, however participants with type 2 diabetes may be eligible

  • Participant must not have an active, known fungal, bacterial, and/or known viral infection

  • Participant must not currently be receiving treatment with warfarin sodium (however, low molecular weight heparin and oral Xa inhibitors are allowed)

  • Participants must not have received > 1 prior line of chemotherapy in the advanced or metastatic setting (Immunotherapy will not be considered a line of chemotherapy)

  • Participants must not have received prior treatment with necitumumab

Where to Participate

14 locations are currently available of 14 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.